Form 4: Palisade Bio Director Awarded 510,700 Restricted Stock Units

Palisade Bio, Inc. director Binxian Wei received an award of 510,700 Restricted Stock Units, aligning his interests with shareholders.

Summary

• Binxian Wei, a Director of Palisade Bio, Inc. (PALI), was granted 510,700 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was October 6, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• RSUs may be settled in cash if the Issuer has insufficient shares reserved under its 2021 Equity Incentive Plan.
• The RSUs are subject to service-based vesting, occurring in three equal annual installments.
• Vesting will be satisfied on the earlier of the next annual meeting of stockholders or the anniversary of October 6, 2025, contingent on continuous service.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating alignment of interests and a commitment to the company's long-term success. It's a routine compensation event, not indicative of extraordinary performance or issues.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• Equity-based compensation is a common practice to attract and retain qualified board members.

Risks

• The RSUs are subject to a service-based vesting requirement, meaning the director must maintain continuous service for the units to vest.
• There is a risk that RSUs may be settled in cash instead of common stock if the company's 2021 Equity Incentive Plan has insufficient reserved shares, which could dilute the intended equity alignment.

Future Outlook

The vesting schedule for the RSUs indicates a future commitment from the director, with equity becoming fully owned over three annual installments, subject to continued service.

Industry Context

The grant of Restricted Stock Units to a director is a standard practice in the biotechnology and broader corporate sectors for executive and board compensation, aiming to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• Equity grants, such as RSUs, are a widely adopted compensation mechanism for directors across various industries, including biotechnology, to foster long-term commitment and performance alignment.
• The three-year vesting schedule is a common structure for such grants, comparable to practices seen in companies like Amgen (AMGN) or Gilead Sciences (GILD) for their non-employee directors, though specific amounts vary based on company size and compensation philosophy.

Corporate Governance

Related Party Transactions

• The grant of 510,700 Restricted Stock Units to Binxian Wei, a director of Palisade Bio, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The RSU grant aims to align the director's financial interests with long-term shareholder value creation.
• Employees: The 2021 Equity Incentive Plan, under which these RSUs were granted, is a broader plan that may also impact employee compensation and retention strategies.

Next Steps

• The RSUs will vest in three equal annual installments, contingent on the director's continuous service.
• The company will need to ensure sufficient shares are reserved under its 2021 Equity Incentive Plan for future settlement of these and other outstanding grants.

Key Dates

Keywords

Palisade Bio, PALI, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Incentive Plan, SEC Form 4